Arcellx reported FY 2025 collaboration revenue of USD 22.3 million, down 79% year over year, which the company attributed primarily to completion of dosing and manufacturing of anito-cel in the iMMagine-1 trial in Q4 2024. R&D expense was USD 157.6 million (flat year over year), G&A expense was USD 117.8 million (+33%), and net loss was USD 228.9 million. Arcellx ended FY 2025 with USD 520.1 million in cash, cash equivalents and marketable securities, and said it believes this is adequate to fund operations into 2028; net cash used in operating activities was USD 210.3 million in FY 2025. On the business side, Arcellx said it submitted a BLA for anito-cel on December 23, 2025 for fourth line or later relapsed or refractory multiple myeloma, and the FDA accepted the BLA with an anticipated PDUFA action date of December 23, 2026. The company also highlighted interim iMMagine-1 data announced in December 2025 and presented at ASH, noted Kite’s ongoing global Phase 3 iMMagine-3 trial (expected to be fully enrolled by mid-2026), and said it began dosing patients in a Phase 1 trial of anito-cel in generalized myasthenia gravis in H2 2025. Separately, Arcellx disclosed it entered into a merger agreement on February 22, 2026 under which Gilead would acquire the company via tender offer for USD 115.00 per share in cash plus one non-tradable CVR per share, with a potential additional USD 5.00 CVR payment tied to cumulative worldwide anito-cel sales exceeding USD 6.0 billion by December 31, 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcellx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-076876), on February 26, 2026, and is solely responsible for the information contained therein.